


medmix Dental: 2-component system 5 mL cartridge

## Our key figures


Our revenue was CHF 241.2 million, a decrease of 2.8% (decrease 6.1% organically), compared with H1 2023. We delivered an adjusted EBITDA margin of 19.1% and free cash flow of CHF 7.6 million.

Share of revenue by market segment  
H1 2024



- 22.8% Dental
- 8.9% Drug Delivery
- 2.8% Surgery
- 27.1% Industry
- 38.5% Beauty

Share of revenue by market segment  
H1 2023



- 21.6% Dental
- 10.8% Drug Delivery
- 3.5% Surgery
- 29.3% Industry
- 34.8% Beauty

## Key figures

### January 1 – June 30

millions of CHF	2024	% of revenue	+/-% change	2023	% of revenue
Revenue	241.2	100.0%	-2.8%	248.1	100.0%
Organic revenue growth <sup>1)</sup>			-6.1%		
Gross profit	80.6	33.4%	-1.7%	82.0	33.1%
Operating income (EBIT)	12.9	5.3%	-11.0%	14.5	5.8%
EBITDA	41.9	17.4%	4.5%	40.0	16.1%
Adjusted EBITDA	46.0	19.1%	-7.4%	49.7	20.0%
Net income attributable to shareholders of medmix Ltd	5.2	2.1%	-29.2%	7.3	2.9%
Adjusted net income	18.2	7.5%	-24.0%	23.9	9.7%
Adjusted diluted earnings per share, attributable to a shareholder of medmix Ltd (in CHF)	0.12		-78.6%	0.58	
Free cash flow (FCF)	7.6		n/a	-4.9	
Adjusted operating net cash flow (adjusted ONCF)	23.9		77.1%	13.5	
Capital expenditure, net (capex, net)	17.1		-51.2%	35.1	
Net debt as of June 30 / December 31	223.2		1.9%	219.0	
Net debt adjusted EBITDA ratio as of June 30 / December 31 <sup>2)</sup>	2.50		6.1%	2.35	
Employees (number of full-time equivalents) as of June 30 / December 31	2'695		1.4%	2'658	

1) Adjusted for currency effects.

2) Adjusted EBITDA for the last 12 months